explore -WSS

explore

author：comprehensive 2025-10-03 00:40:28 - browse：953

CHICAGO — A next-generation CAR-T therapy was able to substantially shrink tumors in patients with liver cancer in early clinical data presented Monday at the American Society of Clinical Oncology annual meeting. The study, though preliminary and small with only 24 patients, represents a triad of firsts for one of the trial’s sponsors.

“It’s the first CAR therapy working in liver cancer. First validation of targeting GPC3 as a target. It’s the first validation of our armoring strategy. And it’s the first of many of our visions of CAR therapy in general,” Matt Hellmann, a medical oncologist and early development oncology lead at AstraZeneca, said in an interview.

This abstract, presented by cancer researcher Qi Zhang of Zhejiang University School of Medicine, is yet another significant showing by AstraZeneca at this ASCO. The company had two plenary presentations on its blockbuster lung cancer drug Tagrisso and immunotherapy drug Imfinzi — as well as new results on Enhertu, which AstraZeneca developed with Daiichi Sankyo.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Akili changes sales model for its ADHD video game treatment

focus

WSS

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

Biden announces an advanced cancer research initiative

'A game

Information blocking fines are now fair game in health care

VC firm RA Capital starts a new synthetic biology incubator

How the messy conversation about Dolly changed bioethics

focus

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

What does generative AI mean for health care? We asked experts

Akili changes sales model for its ADHD video game treatment

Guidelines to prevent youth baseball injuries need more muscle

What happened to the House vote on health price transparency?

Hepatitis C has a cure — but many Americans still lack access to it

The unintended consequences of overturning Roe v. Wade

What does generative AI mean for health care? We asked experts

An outrageous hospital charge: I paid $710 for an hour of babysitting

23andMe had bad news about my health. I wish a person had delivered it

Moscow blames Kyiv for missile attacks in southern Russia as Kremlin forces pound Ukrainian village

hotspot

Trader Joe's recalls 10K cases of broccoli cheddar soup over potential foreign material

As the dark side of IVF slowly comes into focus, even more transparency is needed

Behind warning on Apellis’s eye drug lies a conflict of interest

Information blocking fines are now fair game in health care

Chamber of Commerce, DOJ clash in court over drug prices

Behind warning on Apellis’s eye drug lies a conflict of interest

Wikipedia

focus

focus

focus